Patents by Inventor Mohammed Selman

Mohammed Selman has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11517598
    Abstract: Provided herein are methods for enhancing infection, growth, spread, or titer of an oncolytic RNA virus in a cancer or tumor cell; enhancing the oncolytic activity, cytokine-induced cell death activity, and/or cytotoxic activity of an oncolytic RNA virus in a cancer or tumor cell; upregulating cytokine response to, and/or enhancing the immunotherapeutic activity of an oncolytic RNA virus in a cancer or tumor cell; and/or treating a tumor or cancer in a subject in need thereof. Such methods employ a vanadium-containing compound, administered to the cancer or tumor cells before, after, or concurrently with infection of the cancer or tumor cells with the oncolytic RNA virus. Related compositions, uses, and kits therefor are also provided. Methods for producing RNA viruses, RNA virus-based cancer vaccines, and RNA virus-based cancer gene therapy vectors are also provided.
    Type: Grant
    Filed: October 3, 2017
    Date of Patent: December 6, 2022
    Assignee: Ottawa Hospital Research Institute
    Inventors: Mohammed Selman, Jean-Simon Diallo
  • Publication number: 20200276253
    Abstract: Provided herein are fumaric and maleic acid-containing compounds, compositions comprising the same and methods for using such compounds to enhance production, growth, spread or titer of interferon-sensitive viruses in cells, particularly cancer and tumor cells. Also provided are methods of treating tumors or cancers in a subject by administering the compounds and compositions.
    Type: Application
    Filed: November 23, 2018
    Publication date: September 3, 2020
    Inventors: Jean-Simon Diallo, Mohammed Selman, Rozanne Arulanandam, Nicole Elise Forbes, Ramya Krishnan
  • Publication number: 20190231832
    Abstract: Provided herein are methods for enhancing infection, growth, spread, or titer of an oncolytic RNA virus in a cancer or tumor cell; enhancing the oncolytic activity, cytokine-induced cell death activity, and/or cytotoxic activity of an oncolytic RNA virus in a cancer or tumor cell; upregulating cytokine response to, and/or enhancing the immunotherapeutic activity of an oncolytic RNA virus in a cancer or tumor cell; and/or treating a tumor or cancer in a subject in need thereof. Such methods employ a vanadium-containing compound, administered to the cancer or tumor cells before, after, or concurrently with infection of the cancer or tumor cells with the oncolytic RNA virus. Related compositions, uses, and kits therefor are also provided. Methods for producing RNA viruses, RNA virus-based cancer vaccines, and RNA virus-based cancer gene therapy vectors are also provided.
    Type: Application
    Filed: October 3, 2017
    Publication date: August 1, 2019
    Applicant: Ottawa Hospital Research Institute
    Inventors: Mohammed Selman, Jean-Simon Diallo